 EX-10.10 7 s105258_ex10-10.htm EXHIBIT 10-10
 
Exhibit 10.10
 
Non-Federal
 
Subaward Agreement
 
Prime Awardee 	Subawardee
Institution/Organization ("PRIME RECIPIENT") 	Institution/Organization 
("SUBRECIPIENT")
  	  	  	 
Name: 	Shuttle Pharmaceutical, LLC 	Name: 	Rhode Island Hospital
  	  	  	 
Address: 	1 Research Court, Suite 450 	Address: 	593 Eddy Street
  	Rockville, MD 20850 	  	Providence, RI 02903
  	  	  	 
Prime Award No.
 
Subaward No.
  	HHSN261201400013C 	  	 
  	  	  	 
Sponsor 	
  
 
  	 
  	National Cancer Institute 	  	 
 
Subaward Period of Performance 	Amount Funded this Action 	Est. Total (if 
incrementally funded)
  	  	  	 
Phase I 10/27/14 - 6/18/15 Phase II 6/19/15 - 6/18/17 	$65,549 	$688,818
  	  	  	 
Project Title 	  	 
  	  	  	 
  	Development of Radiation Modulators for Use During Radiotherapy
Reporting Requirements [Check here if applicable: x See Attachment 4]
 
Terms and Conditions
 
1) Prime Recipient hereby awards a cost reimbursable subaward, as described 
above, to Subrecipient. The statement of work and budget for this subaward 
are (check one): ___ as specified in Subrecipient’s proposal dated          
             ; or	 _X_ as shown in Attachments 3 & 4. In its performance of 
subaward work, Subrecipient shall be an independent entity and not an 
employee or agent of Prime Recipient.
2) Prime Recipient shall reimburse Subrecipient not more often than monthly 
for allowable costs. All invoices shall be submitted using Subrecipient’s 
standard invoice, but at a minimum shall include current and cumulative 
costs (including cost sharing), subaward number, and certification as to 
truth and accuracy of invoice. Invoices that do not reference Prime 
Recipient’s subaward number shall be returned to Subrecipient. Invoices and 
questions concerning invoice receipt or payments should be directed to the 
appropriate party’s Financial Contact, as shown in Attachment 2.
3) A final statement of cumulative costs incurred, including cost sharing, 
marked “FINAL,” must be submitted to Prime Recipient’s Administrative 
Contact NOT LATER THAN sixty (60) days after subaward end date. The final 
statement of costs shall constitute Subrecipient’s final financial report.
4) All payments shall be considered provisional and subject to adjustment 
within the total estimated cost in the event such adjustment is necessary 
as a result of an adverse audit finding against the Subrecipient.
5) Matters concerning the technical performance of this subaward should be 
directed to the appropriate party’s Project Director, as shown in 
Attachment 2. Technical reports are required as shown above, “Reporting 
Requirements.”
6) Matters concerning the request or negotiation of any changes in the 
terms, conditions, or amounts cited in this subaward agreement should be 
directed to the appropriate party’s Administrative Contact, as shown in 
Attachment 2. Any such changes made to this subaward agreement require the 
written approval of each party’s Authorized Official, as shown in 
Attachment 2.
7) Each party shall be responsible for its negligent acts or omissions and 
the negligent acts or omissions of its employees, officers or directors, to 
the extent allowed by law.
8) Either party may terminate this agreement with thirty days written 
notice to the appropriate party’s Administrative Contact, as shown in 
Attachment 2. Prime Recipient shall pay Subrecipient for all allowable, 
noncancellable obligations in the event of termination.
9) No-cost extensions require the approval of the Prime Recipient. Any 
requests for a no-cost extension should be addressed to and received by the 
Administrative Contact, as shown in Attachment 2, not less than thirty days 
prior to the desired effective date of the requested change.
10) The Subaward is subject to the terms and conditions of the Prime Award 
and other special terms and conditions, as identified in Attachment 1.
 
By an Authorized Official of PRIME RECIPIENT: 	  	By an Authorized Official 
of SUBRECIPIENT:
  	  	  	  	  	  	 
/s/ Anatoly Dritschilo 	  	10/22/2014 	  	 	  	10/28/2014
  	  	  	  	  	  	 
Anatoly Dritschilo, MD - CEO 	  	Date 	  	  	  	Date
 
Lifespan 3/15/10
 

 

 

 
Non-Federal
 
Attachment 2
Subaward Agreement
 
Prime Recipient Contacts 	Subrecipient Contacts
Administrative Contact 	Administrative Contact
  	 
Name: 	
Peter D. Dritschilo
President & CFO
Name: 	Kim-Marie Lawrence
  	  	  	 
Address: 	
Shuttle Pharmaceuticals, LLC
One Research Court, Suite 450
Rockville, MD 20850-6252
Address: 	
Office of Research Administration
1 Hoppin Street, Suite 1,300
Providence, RI 02903-4141
  	  	  	 
Telephone: 	240-271-0642 	Telephone: 	401.444.8554
Fax: 	301-519-8081 	Fax: 	401.444.4061
Email: 	hoya92@aol.com 	Email: 	klawrence@lifespan.org
  	 
Principal Investigator 	Project Director
  	 
Name: 	Theodore Phillips, MD 	Name: 	
Timothy Kinsella, MD
“Essential to the project.”
  	  	  	 
Address: 	
Shuttle Pharmaceuticals, LLC
One Research Court, Suite 450
Rockville, MD 20850-6252
Address: 	
Rhode Island Hospital
593 Eddy Street, APC 1
Providence, RI 02903
  	  	  	 
Telephone: 	240-403-4212 	Telephone: 	401.444.6203
Fax: 	301-519-8081 	Fax: 	401.444.5335
Email: 	farfa12@aol.com 	Email: 	tkinsella@lifespan.org
  	  	  	 
Financial Contact 	Financial Contact
  	 
Name: 	
Peter D. Dritschilo President & CFO
President & CFO
Name: 	
Donald Hook
Manager, Research Finance
  	  	  	 
Address: 	
Shuttle Pharmaceuticals, LLC
One Research Court, Suite 450
Rockville, MD 20850-6252
Address: 	
Rhode Island Hospital
1 Hoppin Street, Suite 1.300
Providence, RI 02903-4141
  	  	  	 
Telephone: 	240-271-0642 	Telephone: 	401-444-5112
Fax: 	301-519-8081 	Fax: 	401-444-4061
Email: 	hoya92@aol.com 	Email: 	dhook@lifespan.org
  	 
Authorized Official 	Authorized Official
  	 
Name: 	Anatoly Dritschilo, MD CEO 	Name: 	Joan M. Silva
  	  	  	 
Address: 	Shuttle Pharmaceuticals, LLC
One Research Court, Suite 450
Rockville, MD 20850-6252 	Address: 	
Administrative Manager
Rhode Island Hospital
Office of Research Administration
1 Hoppin Street, Suite 1.300
Providence, RI 02903-4141
  	  	  	 
Telephone: 	202-444-4068 	Telephone: 	401.444.4006
Fax: 	301-519-8081 	Fax: 	401.444.4061
Email: 	dritscha@georgetown.edu 	Email: 	jsilva@lifespan.org
 
Lifespan 3/15/10
 

 

 

 
Proposed Budget - Attachment 3
 
701 xxxx
 
IPdR (BrUOG 265)
 
Tim Kinsella, MD 	  	Start 	  	  	10/22/14 	  	  	  	  	  	6/19/15 	  	  	  	
  	  	6/19/16 	  	  	  	 
  	  	End 	  	  	6/18/15 	  	  	  	  	  	6/18/16 	  	  	  	  	  	6/18/17 	  	
  	  	 
Personnel 	  	Salary 	  	  	Cal Mos. 	  	  	Effort 	  	  	Yr 1 	  	  	Cal 
Mos. 	  	  	Effort 	  	  	Yr 2 	  	  	Cal Mos. 	  	  	Effort 	  	  	
 Yr 3
  	  	TOTAL 	 
Tim Kinsella, MD 	  	$ 	181,500 	  	  	  	1.45 	  	  	  	12.1 	% 	  	$ 	
16,448 	  	  	  	2.76 	  	  	  	23 	% 	  	$ 	41,745 	  	  	  	2.76 	  	  	  	
23 	% 	  	$ 	41,557 	  	  	$ 	99,750 	 
Howard Safran, MD 	  	$ 	181,500 	  	  	  	0.47 	  	  	  	3.9 	% 	  	$ 	
5,332 	  	  	  	1.08 	  	  	  	9 	% 	  	$ 	16,335 	  	  	  	1.08 	  	  	  	
9 	% 	  	$ 	16,335 	  	  	$ 	38,002 	 
Andrea Monckeberg, 	  	$ 	125,000 	  	  	  	  	  	  	  	0.0 	% 	  	$ 	0 	  	
  	  	0.36 	  	  	  	3 	% 	  	$ 	3,825 	  	  	  	0.36 	  	  	  	3 	% 	  	$ 	
3,902 	  	  	$ 	7,727 	 
Mark LeGolvan, MD 	  	$ 	181,500 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	
  	0.00 	  	  	  	0 	% 	  	  	  	  	  	  	0.23 	  	  	  	2 	% 	  	$ 	3,479 	
  	  	$ 	3,479 	 
TBN, CRA 	  	  	$53 500 	  	  	  	1 70 	  	  	  	14.2 	% 	  	$ 	5,684 	  	  	
  	1.70 	  	  	  	14.2 	% 	  	$ 	5,798 	  	  	  	1.70 	  	  	  	14.2 	% 	  	
$ 	5,914 	  	  	  	$17 396 	 
TBN, Res Nurse 	  	$ 	87,210 	  	  	  	  	  	  	  	0.0 	% 	  	$ 	0 	  	  	  	
6.60 	  	  	  	55 	% 	  	$ 	47,966 	  	  	  	6.60 	  	  	  	55 	% 	  	$ 	
48,925 	  	  	$ 	96,890 	 
Total Salaries 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	27,464 	  	  	  	
  	  	  	  	  	  	  	$ 	115,669 	  	  	  	  	  	  	  	  	  	  	$ 	120,111 	
  	  	$ 	263,244 	 
Fringe: 	  	  	  	  	  	  	  	  	  	  	31.9 	% 	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
Tim Kinsella, MD 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	5,247 	  	  	  	
  	  	  	  	  	  	  	$ 	13,317 	  	  	  	  	  	  	  	  	  	  	$ 	13,257 	  	
  	$ 	31,820 	 
Howard Safran, MD 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	1,701 	  	  	  	
  	  	  	  	  	  	  	$ 	5,211 	  	  	  	  	  	  	  	  	  	  	$ 	5,211 	  	  	
$ 	12,122 	 
Andrea Monckeberg, 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	
  	  	  	  	  	  	$ 	1,220 	  	  	  	  	  	  	  	  	  	  	$ 	1,245 	  	  	
$ 	2,465 	 
Mark LeGolvan, MD 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	
  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	1,110 	  	  	$ 	
1,110 	 
TBN, CRA 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	1,813 	  	  	  	  	  	  	
  	  	  	  	$ 	1,850 	  	  	  	  	  	  	  	  	  	  	$ 	1,887 	  	  	$ 	
5,549 	 
TBN, Res Nurse 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	
  	  	  	  	  	$ 	15,301 	  	  	  	  	  	  	  	  	  	  	$ 	15,607 	  	  	$ 	
30,908 	 
Total Fringe Benefits 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	8,761 	  	
  	  	  	  	  	  	  	  	  	$ 	36,898 	  	  	  	  	  	  	  	  	  	  	$ 	
38,315 	  	  	$ 	83,975 	 
Total Sal + Fringe 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	36,226 	  	  	
  	  	  	  	  	  	  	  	$ 	152,567 	  	  	  	  	  	  	  	  	  	  	$ 	
158,427 	  	  	$ 	347,219 	 
Equipment 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	
  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
Supplies 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
Animal 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	
  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
Lab Supplies 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	
  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
Total Supplies 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	
  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
Travel 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	
  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
Other 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
Publications 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	
  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
BrUOG 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	5,000 	  	  	  	  	  	  	  	
  	  	  	$ 	37,500 	  	  	  	  	  	  	  	  	  	  	$ 	37,500 	  	  	$ 	
80,000 	 
Biopsy costs/ processing 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	
  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	6,000 	  	  	
$ 	6,000 	 
Total Other 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	5,000 	  	  	  	  	  	
  	  	  	  	  	$ 	37,500 	  	  	  	  	  	  	  	  	  	  	$ 	43,500 	  	  	$ 	
86,000 	 
Total Direct 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	41,226 	  	  	  	  	
  	  	  	  	  	  	$ 	190,067 	  	  	  	  	  	  	  	  	  	  	$ 	201,927 	  	
  	$ 	433,219 	 
Less: Equipment 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	  	  	  	
  	  	  	  	  	$ 	0 	  	  	  	  	  	  	  	  	  	  	$ 	0 	  	  	$ 	0 	 
MTDC Indirect Base x Indirect Rate (59% as of 10/01/11) 	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	
$41,226
59%
  	  	  	  	  	  	  	  	  	  	  	
$190,067
59%
  	  	  	  	  	  	  	  	  	  	  	
$201,927
59%
  	  	  	
$433,219
59%
 
Indirect Costs 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	24,323 	  	  	  	
  	  	  	  	  	  	  	$ 	112,139 	  	  	  	  	  	  	  	  	  	  	$ 	119,137 	
  	  	$ 	255,599 	 
Total Costs 	  	  	  	  	  	  	  	  	  	  	  	  	  	$ 	65,549 	  	  	  	  	
  	  	  	  	  	  	$ 	302,206 	  	  	  	  	  	  	  	  	  	  	$ 	321,063 	  	
  	$ 	688,818 	 
 

 

 

  
ATTACHMENT 4
SUBAWARD AGREEMENT
 
This attachment provides a (1) a statement of flowdown clauses from the 
prime contract # HHSN261201400013C, (2) precedence of the prime contract 
(3)statement of work and (4) reporting requirements for Phase I and Phase 
II.
 
Flowdown Clauses
 
Line 10 of the subaward agreement states "The Subaward is subject to the 
terms and conditions of the Prime Award and other special terms and 
conditions, as identified in Attachment 1.” The Items are in sections H and 
I of the contract # HHSN261201400013, included in Attachment 1.
 
Order of Precedence
 
This Contract, together with the enumerated Attachments (1-4) hereto (all 
of which are incorporated herein by this reference) shall comprise this 
Contract and shall together be referred to as the "Sub-contract Documents.” 
In the event of any inconsistencies between this Contract and the Prime 
Contract HHSN2612014800013C, as included in Attachment 1, the prime 
contract will have precedence in the interpretation or resolution of such 
conflict.
 
Statement of Work - Subcontract
 
I. Background Information and Objectives
 
For NIH review of the Lifespan/RIH subcontract and the subcontract 
statement of work the following summary is provided. The subcontractor will 
work with the PI and the prime contractor to accomplish the following 
tasks. The full SOW is included in the signed contract # HHSN261201400013C.
 
PHASE I SBIR
 
  A. Technical Objectives
 
Objective 1. Activate the IPdR IND for the Phase I and PK clinical trial.
 
Task 1.1. File administrative documents to initially cross-file (IND 
70,333) and obtain an IND for the IPdR and RT clinical trial.
Milestone 1.1. An IPdR IND.
 
Task 1.2. Negotiate with CTEP to transfer sufficient clinical product IPdR 
for performance of the clinical trial.
Milestone 1.2. Clinical product (encapsulated) IPdR, will be made available 
for the proposed Phase I and PK clinical trial at Lifespan/RIH.
 
Lifespan
 

 

 

 
Objective 2. Obtain approvals for the Phase I and PK clinical protocol. 
Develop efficacy protocols satisfying FDA “Orphan Drug” status.
 
Task 2.1. Submit a Letter of Intent (LOI) to NCI CTEP for the Phase I and 
PK clinical studies of IPdR.
Milestone 2.1. LOI approval.
Task 2.2. Submit to the IRB the Phase I and PK study protocol.
Milestone 2.2. IRB approval of the Phase I study for IPdR + RT.
Task 2.3. Consult with the FDA regarding "Orphan Drug” status for IPdR
Milestone 2.3. FDA guidance on "Orphan Drug” status for IPdR for rectal 
cancer.
 
Objective 3. Establish the in-house (Shuttle Pharmaceuticals. LLC 
Laboratories) biomarker assays.
 
Task 3.1 will be performed at NIH and Shuttle Pharmaceuticals
Task 3.2. Prepare a written report of Phase I SBIR achievements to NIH.
Milestone 3.2.NIH accepts the report and exercises the option for Phase II.
 
Gantt Chart 1: Phase I. Milestones, Deliverables, Timeline & Work 
Distribution. between Shuttle Pharmaceuticals, LLC (SP) and Lifespan/Rhode 
Island Hospital (L/RIH).
 
  	  	  	Months
Site 	  	Milestones and Deliverables 	  	1 	  	2 	  	3 	  	4 	  	5 	  	6 	  	
7 	  	8 	  	9
SP, 	  	Objective 1. Task 1.1. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
L/RIH 	  	Milestone 1.1. Activation of the IPdR IND 	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	 
SP 	  	Objective 1. Task 1.2. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
  	  	Milestone 1.2. IPdR clinical product for use in the Phase I clinical 
trial 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
SP 	  	Objective 1. Task 1.3. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
  	  	Milestone 1.3. Capsules of IPdR for Phase I. 	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	 
SP, 	  	Objective 2. Task 2.1. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
L/RIH 	  	Milestone 2.1. CTEP approval of the Phase I and PK LOI. 	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
SP, 	  	Objective 2. Task 2.2. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
L/RIH 	  	Milestone 5. IRB approval of the Phase I clinical trial. 	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
SP 	  	Objective 2. Task 2.3. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
  	  	Milestone 6. FDA advice regarding "Orphan Drug” status for IPdR in 
rectal cancer treatment. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
 
SP 	  	Objective 3. Task 3.1. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
  	  	Milestone 3.1. The GLP %IUdR-DNA cellular incorporation assays 
established in SP laboratories. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	 
SP 	  	Objective 3. Task 3.2. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	 
  	  	Milestone 3.2. NIH approves final report and exercises the Phase II 
option. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
 
Lifespan
 

 

 

 
PHASE II SBIR
 
A. Technical Objectives
 
Objective 1: Perform the Phase I and PK clinical trial of IPdR-mediated 
radiosensitization.
 
Task 1.1. Perform the Phase I clinical trial.
Milestone 1.1. Collect clinical data.
Milestone 1.3. Collect and transfer clinical samples to SP Laboratories for 
analysis.
 
Objective 2: Perform PK analyses to determine optimal dosing schedule.
 
Task 2.1. Determine pharmacokinetics (PK) and %IUdR-DNA for biomarker 
analysis.
Milestone 2.1. Clinical specimens are obtained and analyzed for PK & % 
IUdR-DNA.
Milestone 2.2. PK analyses results.
Milestone 2.3. %IUdR-DNA incorporation results and clinical correlation.
 
Objective 3: Use Phase I and PK results to design the Phase IB/II clinical 
trial.
 
Task 3.1. Analyze the PK data to determine optimal IPdR dosing.
Milestone 3.1. Optimum dosing schedule of IPdR is established.
Task 3.2. Design and write the Phase IB/II protocol for efficacy 
determination.
Milestone 3.2. Phase IB/II clinical protocol for IPdR and RT in rectal 
cancer.
 
Objective 4: Advance the business development and commercialization plan.
 
Task 4.1. Use Phase I clinical trial results to raise capital for efficacy 
clinical trials.
Milestone 4.1. Written business development and commercialization.
Task 4.2. Prepare a final written report for the Government Project 
Officer.
Milestone 4.1. Written final progress report is accepted.
 
Gantt Chart 2: Phase II Milestones, Deliverables and Work Distribution.
 
  	  	  	  	Delivery Schedule (months)
Site 	  	Milestones and Deliverables 	  	2 	  	4 	  	6 	  	8 	  	10 	  	12 	
  	14 	  	16 	  	18 	  	20 	  	22 	  	24
L/RIH 	  	Objective 1. Task 1.1 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	 
  	  	Milestone 1.1. Initiation and performance of the Phase I and PK 
clinical trial of IUdR with RT. Milestone 1.2. Safety and MTD parameters 
for IPdR with RT. Milestone 1.3. Collect and transfer clinical samples to 
SP Labs. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	 
L/RIH 	  	Objective 2. Task 2.1. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	 
SP 	  	Milestone 2.1. Obtain clinical specimens for PK & %IUdR-DNA 
Milestone 2.2. PK analyses Milestone 2.3. %IUdR-DNA incorporation is 
determined and correlated with clinical observations. 	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
SP 	  	Objective 3: Task 3.1. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	 
  	  	Milestone 3.1. Dosing schedule of 	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	 
  	  	IPdR is established, based on PK 	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	 
SP 	  	Objective 3: Task 3.2. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	 
  	  	Milestone 3.2. Written Phase IB/II clinical protocol 	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
SP 	  	Objective 4: Task 4.1. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	 
  	  	Milestone 4.1 Written business and commercialization plan. 	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
SP, 	  	Objective 4: Task 4.2. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	 
L/RIH 	  	Milestone 4.2. Final report submitted to NIH. 	  	  	  	  	  	  	
  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	 
 
Shuttle Pharmaceuticals, LLC (SP); Lifespan/Rhode Island Hospital (L/RIH)
 
Lifespan
 

 

 

  
Reporting Requirements
 
Phase  I 	 
1. 	Kick-off presentation 10/16/14 	 
2. 	Phase I, two quarterly reports 	12/19/14 and 3/19/15
3. 	Draft Updated Commercialization Plan 	5/18/15
4. 	Draft Final Report and Draft Summary of Salient Results 	6/18/15
5. 	Final Commercialization Plan 	6/18/15
6. 	Final Report 	6/18/15
7. 	Final Presentation 	6/18/15
 
Phase II contract activities and reporting will be contingent on the 
Government’s decision to exercise the option per Article B.# of the 
contract # HHSN261201400013C.
 
Phase II 	 
1. 	Option exercised 	(approximately) 6/19/15
2. 	Phase II, quarterly reports exercises 	every 90 days after option
3. 	Draft Final Report for Phase II and Summary of Salient Clinical Trial 
Results 	5/19/17
4. 	Draft Phase II Final Report 	6/19/17
5. 	Phase II Final Report and Presentation 	6/19/17
6. 	Summary of Salient Clinical Trial Results 	6/19/17
 
Additional Reporting and Certifications 	 
  	  	 
7. 	Annual technical progress report for Clinical Research Study 
Populations 	6/19/17
8. 	Protection of Human Subjects 	6/19/15
9. 	Annual Utilization 	6/19/16
10. 	Final Invention Statement and Disclosure 	6/19/17
11. 	Annual Report 	6/19/16
12. 	Conformance Certification 	6/19/15
13. 	Financial Conflict of Interest 	as it arises
14. 	Life Cycle Phase I 	6/18/15
15. 	Life Cycle Phase II Report 1 	6/18/16
16. 	Life Cycle Phase II Report 2 	6/18/17
 
Lifespan
 

 

 